Tribune Therapeutics Secures €23 Million Series A Funding for Anti-Fibrotic Therapies

Novo Holdings has announced its participation in a €23 million Series A funding round for Tribune Therapeutics, a biotechnology company focused on developing anti-fibrotic therapies. The funding round was led by LifeArc Ventures and included other investors such as HealthCap, Innovestor's Life Science Fund, Inven2, Industrifonden, and Investinor. Founded in 2020 by Novo Holdings and HealthCap, Tribune focuses on creating therapies that target key pro-fibrotic pathways to address fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead programme, TRX-44, is designed to prevent scar formation by mimicking the effects of the CCN5 protein, which naturally inhibits pro-fibrotic activities. Tribune's foundation was supported by the Novo Nordisk Foundation through a Pioneer Innovator Grant aimed at advancing scientific discoveries in health and sustainability. Novo Holdings, managing assets of the Novo Nordisk Foundation, is a major life sciences investor focused on long-term returns. This investment represents a significant step forward in advancing unique therapeutic methods for challenging conditions such as fibrosis.